S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
pixel
pixel
Log in
NASDAQ:PCRX

Pacira BioSciences Competitors

$69.20
+1.98 (+2.95 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$64.81
Now: $69.20
$69.40
50-Day Range
$66.08
MA: $72.82
$78.82
52-Week Range
$27.46
Now: $69.20
$80.00
Volume416,274 shs
Average Volume548,588 shs
Market Capitalization$3.04 billion
P/E Ratio24.37
Dividend YieldN/A
Beta1.27

Competitors

Pacira BioSciences (NASDAQ:PCRX) Vs. JNJ, LLY, PFE, ABBV, MRK, and BMY

Should you be buying PCRX stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Pacira BioSciences, including Johnson & Johnson (JNJ), Eli Lilly and (LLY), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Bristol-Myers Squibb (BMY).

Johnson & Johnson (NYSE:JNJ) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, valuation, risk, analyst recommendations and dividends.

Earnings & Valuation

This table compares Johnson & Johnson and Pacira BioSciences' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Johnson & Johnson$82.06 billion5.00$15.12 billion$8.6817.98
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47

Johnson & Johnson has higher revenue and earnings than Pacira BioSciences. Johnson & Johnson is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations and price targets for Johnson & Johnson and Pacira BioSciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Johnson & Johnson031202.80
Pacira BioSciences04702.64

Johnson & Johnson currently has a consensus target price of $178.9333, suggesting a potential upside of 14.63%. Pacira BioSciences has a consensus target price of $76.0909, suggesting a potential upside of 9.96%. Given Johnson & Johnson's stronger consensus rating and higher probable upside, research analysts plainly believe Johnson & Johnson is more favorable than Pacira BioSciences.

Profitability

This table compares Johnson & Johnson and Pacira BioSciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Johnson & Johnson21.01%34.64%13.40%
Pacira BioSciences29.95%10.71%4.88%

Insider and Institutional Ownership

67.3% of Johnson & Johnson shares are held by institutional investors. 0.3% of Johnson & Johnson shares are held by insiders. Comparatively, 5.8% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Johnson & Johnson has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Summary

Johnson & Johnson beats Pacira BioSciences on 10 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Eli Lilly and's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47
Eli Lilly and$22.32 billion8.89$8.32 billion$6.0434.26

Eli Lilly and has higher revenue and earnings than Pacira BioSciences. Eli Lilly and is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Eli Lilly and, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04702.64
Eli Lilly and041012.80

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Eli Lilly and has a consensus price target of $192.60, suggesting a potential downside of 6.92%. Given Pacira BioSciences' higher probable upside, equities research analysts clearly believe Pacira BioSciences is more favorable than Eli Lilly and.

Profitability

This table compares Pacira BioSciences and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
Eli Lilly and24.01%166.45%15.18%

Insider and Institutional Ownership

75.6% of Eli Lilly and shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Pacira BioSciences on 11 of the 15 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Pfizer's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47
Pfizer$51.75 billion3.71$16.27 billion$2.9511.66

Pfizer has higher revenue and earnings than Pacira BioSciences. Pfizer is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Pfizer, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04702.64
Pfizer010402.29

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Pfizer has a consensus price target of $39.5333, suggesting a potential upside of 14.96%. Given Pfizer's higher probable upside, analysts clearly believe Pfizer is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
Pfizer17.85%24.88%9.32%

Insider and Institutional Ownership

67.4% of Pfizer shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.

Pacira BioSciences (NASDAQ:PCRX) and AbbVie (NYSE:ABBV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and AbbVie's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47
AbbVie$33.27 billion5.66$7.88 billion$8.9411.94

AbbVie has higher revenue and earnings than Pacira BioSciences. AbbVie is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and AbbVie, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04702.64
AbbVie131402.72

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. AbbVie has a consensus price target of $115.50, suggesting a potential upside of 8.25%. Given Pacira BioSciences' higher probable upside, equities research analysts clearly believe Pacira BioSciences is more favorable than AbbVie.

Profitability

This table compares Pacira BioSciences and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
AbbVie18.16%439.24%13.22%

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of AbbVie shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, indicating that its stock price is 16% less volatile than the S&P 500.

Summary

AbbVie beats Pacira BioSciences on 8 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Merck & Co., Inc.'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47
Merck & Co., Inc.$46.84 billion3.95$9.84 billion$5.1914.09

Merck & Co., Inc. has higher revenue and earnings than Pacira BioSciences. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04702.64
Merck & Co., Inc.021302.87

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Merck & Co., Inc. has a consensus price target of $95.3571, suggesting a potential upside of 30.39%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
Merck & Co., Inc.24.33%53.83%16.83%

Insider and Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Summary

Merck & Co., Inc. beats Pacira BioSciences on 9 of the 14 factors compared between the two stocks.

Pacira BioSciences (NASDAQ:PCRX) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares Pacira BioSciences and Bristol-Myers Squibb's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pacira BioSciences$421.03 million7.21$-11,020,000.00$0.8680.47
Bristol-Myers Squibb$26.15 billion5.18$3.44 billion$4.6912.88

Bristol-Myers Squibb has higher revenue and earnings than Pacira BioSciences. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Pacira BioSciences and Bristol-Myers Squibb, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pacira BioSciences04702.64
Bristol-Myers Squibb031012.86

Pacira BioSciences currently has a consensus price target of $76.0909, suggesting a potential upside of 9.96%. Bristol-Myers Squibb has a consensus price target of $74.6429, suggesting a potential upside of 23.52%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Pacira BioSciences.

Profitability

This table compares Pacira BioSciences and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pacira BioSciences29.95%10.71%4.88%
Bristol-Myers Squibb-0.11%27.48%10.77%

Insider and Institutional Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. 5.8% of Pacira BioSciences shares are held by company insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Pacira BioSciences has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Pacira BioSciences on 10 of the 15 factors compared between the two stocks.


Pacira BioSciences Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.8$156.10+1.9%$410.34 billion$82.06 billion24.54
Eli Lilly and logo
LLY
Eli Lilly and
2.1$206.92+3.1%$198.32 billion$22.32 billion33.81Gap Up
Pfizer logo
PFE
Pfizer
2.6$34.39+0.6%$191.81 billion$51.75 billion22.19
AbbVie logo
ABBV
AbbVie
2.8$106.70+1.0%$188.42 billion$33.27 billion22.56Insider Selling
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$73.13+1.3%$185.04 billion$46.84 billion16.18
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$60.43+1.8%$135.39 billion$26.15 billion-549.31Dividend Announcement
Zoetis logo
ZTS
Zoetis
2.3$145.68+1.2%$69.22 billion$6.26 billion43.23
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$88.65+2.8%$19.86 billion$1.30 billion24.22
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$42.54+0.5%$16.51 billionN/A0.00Insider Selling
News Coverage
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$164.75+2.6%$9.28 billion$2.16 billion51.97Analyst Report
Increase in Short Interest
Perrigo logo
PRGO
Perrigo
2.6$41.04+1.1%$5.46 billion$4.84 billion-683.89Earnings Announcement
Analyst Report
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.1$22.31+0.3%$4.06 billion$114.62 million-9.00Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.6$24.55+2.9%$2.88 billion$306.49 million27.58
Endo International logo
ENDP
Endo International
1.1$6.99+1.4%$1.61 billion$2.91 billion-10.28Analyst Report
Analyst Revision
News Coverage
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.6$25.15+4.0%$1.32 billion$392.76 million10.43Analyst Downgrade
Gap Up
Zogenix logo
ZGNX
Zogenix
1.7$20.74+2.3%$1.15 billion$3.65 million-2.18
Omeros logo
OMER
Omeros
1.4$18.48+4.1%$1.14 billion$111.81 million-7.76Earnings Announcement
Analyst Revision
Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.2$4.05+0.7%$409.50 million$111.39 million28.93Upcoming Earnings
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.10+0.6%$324.05 million$16.54 million-2.89Analyst Report
Analyst Revision
News Coverage
Lannett logo
LCI
Lannett
2.0$6.17+2.1%$255.45 million$545.74 million-8.57Gap Up
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.48+3.3%$171.34 million$15.96 million-2.72Analyst Report
Analyst Revision
Gap Down
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.12+2.6%$46.78 million$47.53 million-14.16Upcoming Earnings
Gap Down
This page was last updated on 3/7/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.